🔗 Share this article Patients Coming Off Anti-Obesity Medications Regain Weight at a Quadrupled Rate Than Dieters Obesity treatment often requires long-term strategies. A recent study reveals that individuals who discontinue blockbuster weight-loss injections like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt conventional lifestyle programs. Findings released in a prominent medical journal points out that while overweight people can lose about a fifth of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit. "People using such medications need to be informed of the potential of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb. Such speed of regain means a return to pre-treatment weight within about a year and a half. Weighing Approaches The analysis, which examined dozens of studies involving thousands of patients, contrasted the results of the injectable medications with conventional dieting. The team emphasize that people who lose weight through diet and exercise typically experience a less rapid weight regain—approximately 100 grams monthly—post-intervention. Explaining the Quick Regain Doctors believe the mechanism of the drugs explains the amplified rebound. GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite. "Long-term administration of the hormone levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert. "Discontinuation of this medication leads to appetite is no longer kept in check, making excessive eating much more probable." A Lifelong Condition? Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes. Professionals argue that, considering the significant potential of weight regain, the therapy might need to be long-term. This perspective is echoed by drug manufacturers, who note that the results "highlight the long-term nature of excess weight," similar to managing diseases like diabetes. Patient Accounts People who have stopped the medication explain a sudden resurgence of appetite. "It was like a switch that goes on and I was suddenly ravenous," described a patient. The struggle is exacerbated if users have not established permanent dietary or behavioural modifications during therapy. Significant Adoption Figures show that a significant number of people in the UK have tried these injections in the past year, with desire continuing to grow. Use is higher among women compared to males. The middle-aged demographic shows the highest level of interest. Many access the drugs through private prescriptions rather than public health services. Ultimately, experts emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural management.
Obesity treatment often requires long-term strategies. A recent study reveals that individuals who discontinue blockbuster weight-loss injections like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt conventional lifestyle programs. Findings released in a prominent medical journal points out that while overweight people can lose about a fifth of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit. "People using such medications need to be informed of the potential of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb. Such speed of regain means a return to pre-treatment weight within about a year and a half. Weighing Approaches The analysis, which examined dozens of studies involving thousands of patients, contrasted the results of the injectable medications with conventional dieting. The team emphasize that people who lose weight through diet and exercise typically experience a less rapid weight regain—approximately 100 grams monthly—post-intervention. Explaining the Quick Regain Doctors believe the mechanism of the drugs explains the amplified rebound. GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite. "Long-term administration of the hormone levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert. "Discontinuation of this medication leads to appetite is no longer kept in check, making excessive eating much more probable." A Lifelong Condition? Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes. Professionals argue that, considering the significant potential of weight regain, the therapy might need to be long-term. This perspective is echoed by drug manufacturers, who note that the results "highlight the long-term nature of excess weight," similar to managing diseases like diabetes. Patient Accounts People who have stopped the medication explain a sudden resurgence of appetite. "It was like a switch that goes on and I was suddenly ravenous," described a patient. The struggle is exacerbated if users have not established permanent dietary or behavioural modifications during therapy. Significant Adoption Figures show that a significant number of people in the UK have tried these injections in the past year, with desire continuing to grow. Use is higher among women compared to males. The middle-aged demographic shows the highest level of interest. Many access the drugs through private prescriptions rather than public health services. Ultimately, experts emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural management.